Farhad Zaker

Farhad Zaker

Auto-generated profile, based on publicly available information

Farhad Zaker

Department of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2013 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
PDF file
MSMohamad Jafar Sharifi
Mohamad Jafar Sharifi
GBGholamreza Bahoush
Gholamreza Bahoush
FZFarhad Zaker
Farhad Zaker
SAShahla Ansari
Shahla Ansari
KRKhadijeh Arjmandi Rafsanjani
Khadijeh Arjmandi Rafsanjani
HSHeidar Sharafi
Heidar Sharafi
Acute lymphoblastic leukemia patients after being treated with methotrexate, have differences in methotrexate serum levels and toxic side effects. One of the main determinants of these toxic side effects is the host pharmacogenetics. The aim of this study was to evaluate the association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with serum levels, and toxic side effects of methotrexate in childhood acute lymphoblastic leukemia. Applying polymerase chain reaction and restriction fragment length polymorphism techniques, the prevalence of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms was evaluated in 65 acute lymphoblastic leukemia patients. The relationship between polymorphisms and methotrexate serum levels and toxicities was studied. A reverse significant relationship was detected between 3972T allele carriers and hepatotoxicity (P = 0.01, OR = 0.25, 95% CI = 0.09–0.72). Also, 1249A allele carriers had increased rate of gastrointestinal toxicity (P = 0.05, OR = 3.47, 95% CI = 1.04–11.57). No significant relationship was detected between -24CT polymorphism and methotrexate toxic side effects. There was no significant relationship between these three polymorphisms and methotrexate serum levels. Genotyping for 3972CT and 1249GA ABCC2 gene variants maybe useful in acute lymphoblastic leukemia to optimize methotrexate therapy and reducing the associated toxicity.

5 May 2013 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SHSaeed Hassani
Saeed Hassani
SGSeyed H. Ghaffari
Seyed H. Ghaffari
FZFarhad Zaker
Farhad Zaker
RMRohellah Mirzaee
Rohellah Mirzaee
HMHajar Mardani
Hajar Mardani
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh

8 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NRNahid Ramezanpour
Nahid Ramezanpour
FZFarhad Zaker
Farhad Zaker
Arijit BiswasArijit Biswas
Arijit Biswas
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
Background: Congenital factor (F) VII deficiency is a rare coagulation factor deficiency with an estimated incidence of 1 per 500,000 individuals. Patients with severe FVII deficiency present a broad range of clinical presentations. Alloimmunization against exogenous FVII, as the main challenge of replacement therapy, is an extremely rare phenomenon that is accompanied by a high rate of life-threatening bleeding, that renders replacement therapy less effective. Due to the importance of the issue, we performed a systematic literature review in order to assess incidence, molecular basis, clinical presentations, and therapeutic challenge and management of inhibitor in congenital FVII deficiency. Strategy of search: This systematic review was performed in accordance with PRISMA guidelines. We performed an English-language literature review in the PubMed, EMBASE, Scopus, and Google Scholar databases, using the following keywords: “factor VII inhibitor”, “factor VII inhibitors”, “FVII inhibitors”, “congenital FVII deficiency”, “recombinant factor VII”, “anti rFVIIa”, “replacement therapy”, and “alloantibody”. Results: Out of 380 patients in the 13 studies, 27 had inhibitor against FVII; 18 were male, 7 were female, while the sex of 2 was not stated. The majority (92%) developed a high-titer inhibitor (Bethesda Unit > 5). All patients had severe FVII deficiency (FVII:C < 10%), and the majority received recombinant FVII prior to inhibitor development (N: 24, 89%). Among ten patients with a detected mutation, three subjects had a common non-sense (30%), and two had a deletion (20%). Conclusions: Inhibitor development is a relatively rare phenomenon seen only in severe FVII deficiency, where it is associated with severe and life-threatening presentations, treatment challenge, and economic burden on the patients and their families.

19 August 2021 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
PDF file
SBSaeid Barzegar
Saeid Barzegar
AKAmir Asri Kojabad
Amir Asri Kojabad
RSRima Manafi Shabestari
Rima Manafi Shabestari
MBMehdi Barati
Mehdi Barati
MRMohammad Reza Rezvany
Mohammad Reza Rezvany
FZFarhad Zaker
Farhad Zaker

22 June 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MKMasoumeh Kiani-Zadeh
Masoumeh Kiani-Zadeh
MRMohammad Reza Rezvany
Mohammad Reza Rezvany
SNSoodeh Namjoo
Soodeh Namjoo
MBMahmood Barati
Mahmood Barati
MMMohammad Hossein Mohammadi
Mohammad Hossein Mohammadi
LTLadan Teimoori-Toolabi
Ladan Teimoori-Toolabi

21 May 2024 in BioMed Research International
Verified
Journal Article
Open access
PDF file
TTTahere Tabatabaei
Tahere Tabatabaei
MRMohammad Reza Rezvany
Mohammad Reza Rezvany
BGBahare Ghasemi
Bahare Ghasemi
FVFarzane Vafaei
Farzane Vafaei
MZMasoumeh Kiani Zadeh
Masoumeh Kiani Zadeh
ASArash Salmaninejad
Arash Salmaninejad
Epigenetic alterations have been observed in many hematological malignancies, including acute myeloid leukemia (AML). Many of these alterations result from mutations in DNA methyl transferase (DNMT) enzymes, disabling them to methylate target genes in a proper way. In this case-control study, we investigated the association between R882H mutation in DNMT3A gene and DDX43 gene methylation in patients with AML. 47 AML patients and 6 controls were included in this study. After DNA extraction, amplification refractory mutation system (ARMS)-PCR was used to evaluate R882H mutations in DNMT3A gene. The high-resolution melting (HRM) method was used to determine the methylation changes of the DDX43 gene promoter. R882H mutation was only found in 10.6% (5 out of 47) of AML patients. The frequency of DDX43 gene methylation was significantly higher in patients without R882H mutations compared to patients with R882H mutations (P<0.05). The DNMT3A R882H mutation is typically present in a minority of AML patients. Nevertheless, this mutation is associated with a reduced frequency of methylation in the DDX43 promoter region.